The data showed that following treatment, patients with HAE experienced a significant decrease in plasma kallikrein and related angioedema attacks (clinical trial: “NTLA-2002 in adults with hereditary angioedema (HAE) (NTLA-2002)” conducted by Intellia) (https://clinicaltrials.gov/study/NCT05120830). This evidence concerns the gene KLK4 and hereditary angioedema.